Telemedicine/AI – PULMONARY HYPERTENSION

Estimating mean pulmonary arterial pressure (mPAP) in the machine learning era, European Respiratory Journal, October 9, 2026

Accurate assessment of mean pulmonary arterial pressure (mPAP) is key to the diagnosis, haemodynamic classification and follow-up of pulmonary hypertension. The article, authored by French researcher at Le Kremlin-Bicêtre, France, requires permissions in order to access the full text, so we are only able to use the shareable abstract which reads “Large real-world datasets analysed […]

Estimating mean pulmonary arterial pressure (mPAP) in the machine learning era, European Respiratory Journal, October 9, 2026 Read Post »

What’s new on the Pulmonary Hypertension Knowledge Platform – September 2026

September was a busy month in the pulmonary hypertension world, with the European Society of Cardiology (ESC) and European Respiratory Society Congresses (ERS) bringing a wave of new research. The most important news is the update of the ERS Clinical Practice Guidelines for the treatment of pulmonary arterial hypertension (PAH), presented in Barcelona. AfPH Vice

What’s new on the Pulmonary Hypertension Knowledge Platform – September 2026 Read Post »

Join our prestigious panel of speakers on September 28 at 6 pm CEST to gain expert insights on how the new advances in science and AI can improve pulmonary arterial hypertension care!

The Alliance for Pulmonary Hypertension (AfPH) is back with the third instalment of their 2026 webinar series exploring how new science and AI are transforming pulmonary arterial hypertension care. This session taking place on September 28 at 6 pm CEST brings together leading experts from the US, UK, and Netherlands to explore where the field

Join our prestigious panel of speakers on September 28 at 6 pm CEST to gain expert insights on how the new advances in science and AI can improve pulmonary arterial hypertension care! Read Post »

The Ethical Application of Artificial Intelligence in Digital Health, European Heart Journal – Digital Health, Volume 7, Issue 6, July 2026

A recent article by Dr. Iain Armstrong and Peter Winter examines a critical blind spot in digital health ethics known as “misrecognition”, which occurs when artificial intelligence systems evaluate patients solely through easily quantifiable metrics. By prioritizing standardized data over the complex, subjective realities of living with a chronic illness, AI tools inadvertently foster epistemic

The Ethical Application of Artificial Intelligence in Digital Health, European Heart Journal – Digital Health, Volume 7, Issue 6, July 2026 Read Post »

The e-book for the May 2026 edition of Transplant International is available online in open access

The e-book for the May 2026 edition of Transplant International is available online in open access at this link The cover features a letter to the editors reporting the impressive summiting of Aconcagua, the highest peak in the Americas, without supplemental oxygen by a lung transplant recipient accompanied by the medico-surgical team from Medical University

The e-book for the May 2026 edition of Transplant International is available online in open access Read Post »

American Thoracic Society (ATS) annual conference 2026 discussions on AI, Innovation, and Humanism in medicine, American Medical Journal, July 1, 2026

The American Thoracic Society (ATS)’s annual international conference, held in Orlando in May 2026, drew over 14,000 participants from more than 100 countries for six days of scientific sessions, clinical trials, and educational programming. The overarching theme was a field in transition — one being reshaped by artificial intelligence and precision medicine, while holding firm

American Thoracic Society (ATS) annual conference 2026 discussions on AI, Innovation, and Humanism in medicine, American Medical Journal, July 1, 2026 Read Post »

Remote exercise assessment in pulmonary hypertension, Current Opinions in Pulmonary Medicine, May 7, 2026

Assessment of exercise provides important prognostic information about pulmonary arterial hypertension patients. Researchers from the UK have recently published a review of current digital alternatives to traditional outcome measures. The 6-minute walk test (6MWT) is a key tool for monitoring pulmonary arterial hypertension, but since care is often centralized, patients may only do it once

Remote exercise assessment in pulmonary hypertension, Current Opinions in Pulmonary Medicine, May 7, 2026 Read Post »

Monthly roundup of content shared on the Pulmonary Hypertension Knowledge Sharing Platform – April 2026

Welcome to our April roundup of the most relevant and interesting content shared on this platform. April 2026 has been a particularly rich month, with significant news on the diagnostics, clinical trials and treatment front alongside important research on quality of life, patient preferences information, economic burden. There is also a selection of patient resources

Monthly roundup of content shared on the Pulmonary Hypertension Knowledge Sharing Platform – April 2026 Read Post »

Review of Pulmonary Arterial Hypertension (PAH) research in 2025: key trends and what they mean for patients, Pulmonary Therapy, April 8, 2026

A descriptive analysis of 54 pulmonary arterial hypertension-related clinical studies registered on international platforms in 2025 was recently published in Pulmonary Therapeutics. The review reveals an evolving and increasingly sophisticated research landscape. Nearly two thirds of the studies were interventional and one third observational, with most involving pharmacological interventions. Most trials involved pharmacological interventions and

Review of Pulmonary Arterial Hypertension (PAH) research in 2025: key trends and what they mean for patients, Pulmonary Therapy, April 8, 2026 Read Post »

Telemedicine trends post Covid-19, Journal of Internal General Medicine, February 11, 2026

A large retrospective cohort study analyzed outpatient visits across five hospitals within the University of Pennsylvania Health System (Penn Medicine) from January 1, 2019, to September 30, 2024. The study included 46,149,734 visits among 2,248,341 patients. Telemedicine surged from 1% of visits pre-pandemic to 17% in April 2020, before stabilising at 4-6% from 2022 onwards.

Telemedicine trends post Covid-19, Journal of Internal General Medicine, February 11, 2026 Read Post »

Detecting pulmonary hypertension earlier? US Food and Drug Administration (FDA) clears Anumana’s AI echocardiogram algorithm

Anumana has received US Food and Drug Administration (FDA) 510(k) clearance for an AI-powered algorithm that detects early signs of pulmonary hypertension using standard 12-lead echocardiograms (ECGs) — making it the first pulmonary hypertension algorithm cleared for this widely available diagnostic tool. Previously granted US Food and Drug Administration “Breakthrough Device Designation”, the algorithm integrates

Detecting pulmonary hypertension earlier? US Food and Drug Administration (FDA) clears Anumana’s AI echocardiogram algorithm Read Post »

Assessing the feasibility of using smartphone data to identify risk of idiopathic pulmonary arterial hypertension, NPJ Vascular Health, March 25, 2026

A UK pilot study explored whether physical activity data from wearable devices and a smartphone app (My Heart Counts) could help detect idiopathic pulmonary arterial hypertension (IPAH) earlier, before formal diagnosis. Analysing up to eight years of real-world activity and heart rate data from 109 participants, including patients with idiopathic pulmonary arterial hypertension, disease controls,

Assessing the feasibility of using smartphone data to identify risk of idiopathic pulmonary arterial hypertension, NPJ Vascular Health, March 25, 2026 Read Post »

“Making the most of remote appointments”, the UK Pulmonary Hypertension Association’s free information material of the month

The UK Pulmonary Hypertension Association’s free form has been designed to help patients prepare for remote medical appointments. Completing it it beforehand can help make the most of the visits. Download the form at this link on the PHA UK website

“Making the most of remote appointments”, the UK Pulmonary Hypertension Association’s free information material of the month Read Post »

Telehealth in rural areas: Bridging the gaps through policy drivers, Intelligent Hospital, December 2025 issue

In an article published in the December 2025 issue of Intelligent Hospital on the challenges of telehealth adoption in rural communities, the authors examine why telehealth uptake remains limited outside urban areas despite its growing role in modern healthcare. The study explains that although technology has transformed health services by improving clinical capabilities and patient

Telehealth in rural areas: Bridging the gaps through policy drivers, Intelligent Hospital, December 2025 issue Read Post »

“Heart Works” – phaware® – a New Pulmonary Hypertension App from Phaware Global Association®

“Heart Works” key features: Real-time health data tracking: including advanced quality-of-life surveys and 6-minute walk tests, allowing patients to closely monitor their progression. Access to Phaware resources: 500+ curated phaware® podcasts, webinars, and expert interviews on pulmonary hypertension. Access to international resources: Thanks to partnerships with leading organizations including Stanford Wall Center, University of Alberta,

“Heart Works” – phaware® – a New Pulmonary Hypertension App from Phaware Global Association® Read Post »

Study provides proof-of-concept that fully automated, algorithm-driven tacrolimus dosing can improve therapeutic drug monitoring in real-world clinical practice, Clinical Pharmacology and Therapeutics, October 11, 2025

Tacrolimus therapeutic drug monitoring is challenging due to high inter- and intra-patient variability. A prospective randomized controlled trial was conducted by researchers at the University Hospital in Leuven, Belgium, on 293 de novo kidney transplant recipients during the first 14 days post-transplant. A fully automated Model-informed precision dosing (MIPD) application (1) was integrated into the

Study provides proof-of-concept that fully automated, algorithm-driven tacrolimus dosing can improve therapeutic drug monitoring in real-world clinical practice, Clinical Pharmacology and Therapeutics, October 11, 2025 Read Post »

Shaping the Future of Digital Health Technology (DHT) Assessment, Journal of Market Access & Health Policy, September 4, 2025

A 2025 study published in the Journal of Market Access & Health Policy explores the evolving role of digital health technologies in shaping patient experiences and healthcare delivery. The authors used a mixed-methods approach including a survey of 20 Digital Health Technology developers, and qualitative research with 29 industry representatives from startups to multinational companies

Shaping the Future of Digital Health Technology (DHT) Assessment, Journal of Market Access & Health Policy, September 4, 2025 Read Post »

Deep Learning Models Can Identify Pulmonary Arterial Hypertension associated with Congenital Heart Disease (CHD-PAH) on Routine Chest X-Ray, The Cardiology Advisor, September 5, 2025

Key point: The deep learning-based chest X-ray model for pulmonary hypertension detection, CXR-PH-Net, proved particularly sensitive in identifying in early-stage/mild pulmonary hypertension. Researchers in China developed artificial intelligence programs that can analyze chest X-rays to detect pulmonary hypertension by training computer programs using chest X-rays from over 6,700 patients in Beijing hospitals, comparing those with and

Deep Learning Models Can Identify Pulmonary Arterial Hypertension associated with Congenital Heart Disease (CHD-PAH) on Routine Chest X-Ray, The Cardiology Advisor, September 5, 2025 Read Post »

Computer modeling used in study to simulate long-term mortality/morbidity in patients with pulmonary arterial hypertension If sotatercept Is delayed, Advances in Therapy, June 17, 2025

Researchers used computer modeling to compare immediate versus delayed (2-year) treatment with sotatercept, a new pulmonary arterial hypertension medication, to predict lifetime outcomes. Study Method: Building on the findings of the phase 3 STELLAR trial on sotatercept the authors of the study refer to a population health model which was recently published assessing the long-term

Computer modeling used in study to simulate long-term mortality/morbidity in patients with pulmonary arterial hypertension If sotatercept Is delayed, Advances in Therapy, June 17, 2025 Read Post »

Artificial intelligence applied to chest X-rays may have the potential to detect pulmonary hypertension associated with congenital heart disease (PAH-CHD), CHEST Journal, June 18, 2025

Pulmonary hypertension (PH) is hard to diagnose, especially in places with limited medical resources, but catching it early is crucial for treatment. A group of researchers from China conducted a retrospective cohort study with 4,576 patients, including 2,288 pulmonary hypertension cases, who underwent chest X-rays (CXR) followed by right heart catheterization (RHC) or transthoracic echocardiography

Artificial intelligence applied to chest X-rays may have the potential to detect pulmonary hypertension associated with congenital heart disease (PAH-CHD), CHEST Journal, June 18, 2025 Read Post »